journal
MENU ▼
Read by QxMD icon Read
search

JAMA Oncology

journal
https://www.readbyqxmd.com/read/28542690/insurance-coverage-and-aid-in-dying-medication-costs-reply
#1
Veena Shankaran, Richard J LaFrance, Scott D Ramsey
No abstract text is available yet for this article.
May 25, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28542687/chemotherapy-induced-hair-loss-alopecia
#2
Howard Jack West
No abstract text is available yet for this article.
May 25, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28542680/bourbon
#3
Ajay Major
No abstract text is available yet for this article.
May 25, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28542679/patterns-of-treatment-failure-and-postrecurrence-outcomes-among-patients-with-locally-advanced-head-and-neck-squamous-cell-carcinoma-after-chemoradiotherapy-using-modern-radiation-techniques
#4
Jonathan E Leeman, Jin-Gao Li, Xin Pei, Praveen Venigalla, Zachary S Zumsteg, Evangelia Katsoulakis, Eitan Lupovitch, Sean M McBride, Chiaojung J Tsai, Jay O Boyle, Benjamin R Roman, Luc G T Morris, Lara A Dunn, Eric J Sherman, Nancy Y Lee, Nadeem Riaz
Importance: Even though 15% to 50% of patients with head and neck squamous cell carcinoma (HNSCC) experience recurrence, relatively little is known regarding patterns of treatment failure and postrecurrence outcomes after chemoradiotherapy using modern radiation techniques (intensity-modulated radiotherapy [IMRT]). Recurrence patterns are significantly affected by variations in the quality of radiotherapy, which may confound findings from multicenter trials. Objective: To assess patterns of treatment failure and postrecurrence outcomes for patients with HNSCC treated with contemporary radiotherapy techniques...
May 25, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28542677/association-of-previous-clinical-breast-examination-with-reduced-delays-and-earlier-stage-breast-cancer-diagnosis-among-women-in-peru
#5
Anya Romanoff, Tara Hayes Constant, Kay M Johnson, Manuel Cedano Guadiamos, Ana María Burga Vega, Joseph Zunt, Benjamin O Anderson
Importance: Mammographic screening is impractical in most of the world where breast cancers are first identified based on clinical signs and symptoms. Clinical breast examination may improve early diagnosis directly by finding breast cancers at earlier stages or indirectly by heightening women's awareness of breast health concerns. Objective: To investigate factors that influence time to presentation and stage at diagnosis among patients with breast cancer to determine whether history of previous clinical breast examination is associated with earlier presentation and/or earlier cancer stage at diagnosis...
May 25, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28542674/insurance-coverage-and-aid-in-dying-medication-costs
#6
David Grube, Ashley Cardenas
No abstract text is available yet for this article.
May 25, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28542671/folfoxiri-plus-bevacizumab-as-conversion-therapy-for-patients-with-initially-unresectable-metastatic-colorectal-cancer-a-systematic-review-and-pooled-analysis
#7
Gianluca Tomasello, Fausto Petrelli, Michele Ghidini, Alessandro Russo, Rodolfo Passalacqua, Sandro Barni
Importance: The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for metastatic colorectal cancer. However, resection rates of metastases and overall survival with this schedule have never been systematically evaluated in published studies including, but not limited to, the TRIBE (TRIplet plus BEvacizumab) trial. Objective: To assess the clinical efficacy of FOLFOXIRI-Bev, including outcomes and rates of surgical conversions...
May 25, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28520919/association-of-interactive-reminders-and-automated-messages-with-persistent-adherence-to-colorectal-cancer-screening-a-randomized-clinical-trial
#8
Martin C S Wong, Jessica Y L Ching, Thomas Y T Lam, Simpson K C Ng, John C T Wong, Justin C Y Wu, Francis K L Chan
No abstract text is available yet for this article.
May 18, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28520831/current-challenges-associated-with-next-generation-sequencing-of-breast-cancer
#9
Steven Sorscher
No abstract text is available yet for this article.
May 18, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28520829/association-between-combined-tmprss2-erg-and-pca3-rna-urinary-testing-and-detection-of-aggressive-prostate-cancer
#10
Martin G Sanda, Ziding Feng, David H Howard, Scott A Tomlins, Lori J Sokoll, Daniel W Chan, Meredith M Regan, Jack Groskopf, Jonathan Chipman, Dattatraya H Patil, Simpa S Salami, Douglas S Scherr, Jacob Kagan, Sudhir Srivastava, Ian M Thompson, Javed Siddiqui, Jing Fan, Aron Y Joon, Leonidas E Bantis, Mark A Rubin, Arul M Chinnayian, John T Wei, Mohamed Bidair, Adam Kibel, Daniel W Lin, Yair Lotan, Alan Partin, Samir Taneja
Importance: Potential survival benefits from treating aggressive (Gleason score, ≥7) early-stage prostate cancer are undermined by harms from unnecessary prostate biopsy and overdiagnosis of indolent disease. Objective: To evaluate the a priori primary hypothesis that combined measurement of PCA3 and TMPRSS2:ERG (T2:ERG) RNA in the urine after digital rectal examination would improve specificity over measurement of prostate-specific antigen alone for detecting cancer with Gleason score of 7 or higher...
May 18, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28520828/targeted-therapy-as-an-alternative-to-whole-brain-radiotherapy-in-egfr-mutant-or-alk-positive-non-small-cell-lung-cancer-with-brain-metastases
#11
Pablo Martínez, Raymond H Mak, Geoffrey R Oxnard
Clinical Question: Is up-front whole-brain radiotherapy required to treat multiple brain metastases from non-small-cell lung cancer when highly active targeted therapies are available? Clinical Application: Patients with EGFR-mutant or ALK-positive non-small-cell lung cancer with brain metastases now have the potential to achieve a prolonged survival. Through use of highly active targeted therapies, whole-brain radiotherapy can be safely postponed, diminishing toxic effects that could impair quality of life...
May 18, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28520826/current-challenges-associated-with-next-generation-sequencing-of-breast-cancer-reply
#12
Polly Niravath, Burcu Cakar, Matthew Ellis
No abstract text is available yet for this article.
May 18, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28520825/toward-palliative-care-for-all-patients-with-advanced-cancer
#13
Yael Schenker, Robert Arnold
No abstract text is available yet for this article.
May 18, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28520824/expanding-purpura-in-a-neutropenic-patient
#14
Zoe O Brown-Joel, Nahid Y Vidal, Karolyn A Wanat
No abstract text is available yet for this article.
May 18, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28494073/associations-of-luminal-and-basal-subtyping-of-prostate-cancer-with-prognosis-and-response-to-androgen-deprivation-therapy
#15
Shuang G Zhao, S Laura Chang, Nicholas Erho, Menggang Yu, Jonathan Lehrer, Mohammed Alshalalfa, Corey Speers, Matthew R Cooperberg, Won Kim, Charles J Ryan, Robert B Den, Stephen J Freedland, Edwin Posadas, Howard Sandler, Eric A Klein, Peter Black, Roland Seiler, Scott A Tomlins, Arul M Chinnaiyan, Robert B Jenkins, Elai Davicioni, Ashley E Ross, Edward M Schaeffer, Paul L Nguyen, Peter R Carroll, R Jeffrey Karnes, Daniel E Spratt, Felix Y Feng
Importance: There is a clear need for a molecular subtyping approach in prostate cancer to identify clinically distinct subgroups that benefit from specific therapies. Objectives: To identify prostate cancer subtypes based on luminal and basal lineage and to determine associations with clinical outcomes and response to treatment. Design, Setting, and Participants: The PAM50 classifier was used to subtype 1567 retrospectively collected (median follow-up, 10 years) and 2215 prospectively collected prostate cancer samples into luminal- and basal-like subtypes...
May 11, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28494072/prognostic-and-predictive-value-of-a-breast-cancer-expression-signature-in-localized-prostate-cancer
#16
Wassim Abida, Howard I Scher
No abstract text is available yet for this article.
May 11, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28494064/myeloma-minimal-residual-disease-and-surrogacy
#17
Richard F Little, Lisa M McShane, Boris Freidlin
No abstract text is available yet for this article.
May 11, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28494053/myeloma-minimal-residual-disease-and-surrogacy-reply
#18
Nikhil Munshi, Mehmet Kemal Samur, Walter Gregory
No abstract text is available yet for this article.
May 11, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28494052/association-of-minimal-residual-disease-with-clinical-outcome-in-pediatric-and-adult-acute-lymphoblastic-leukemia-a-meta-analysis
#19
Donald A Berry, Shouhao Zhou, Howard Higley, Lata Mukundan, Shuangshuang Fu, Gregory H Reaman, Brent L Wood, Gary J Kelloff, J Milburn Jessup, Jerald P Radich
Importance: Minimal residual disease (MRD) refers to the presence of disease in cases deemed to be in complete remission by conventional pathologic analysis. Assessing the association of MRD status following induction therapy in patients with acute lymphoblastic leukemia (ALL) with relapse and mortality may improve the efficiency of clinical trials and accelerate drug development. Objective: To quantify the relationships between event-free survival (EFS) and overall survival (OS) with MRD status in pediatric and adult ALL using publications of clinical trials and other databases...
May 11, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28494051/declining-incidence-rates-of-prostate-cancer-in-the-united-states-is-this-good-news-or-not
#20
Mary K Downer, Meir J Stampfer, Matthew R Cooperberg
No abstract text is available yet for this article.
May 11, 2017: JAMA Oncology
journal
journal
50067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"